Synthesis and Biological Evaluation of Novel Anti-leukemia Proteolysis-Targeting Chimeras in Degradating Inosine Monophosphate Dehydrogenase

AuthorHamidreza Sohbatien
AuthorMohsen Aminien
AuthorSaeed Balalaieen
OrcidSaeed Balalaie [0000-0002-5764-0442]en
Issued Date2022-12-31en
AbstractBackground: Proteolysis-targeting chimera (PROTAC) is a bifunctional molecule comprising a ligand to recognize the targeted protein to be degraded. Objectives: To use the advantages of the PROTAC technique, we have synthesized novel compounds to degrade inosine monophosphate dehydrogenase (IMPDH) by the proteasome system. Methods: We describe the synthesis of new PROTACs based on a combination of mycophenolic acid (MPA) as the potent IMPDH inhibitor and pomalidomide as a ligand of E3 ubiquitin ligase via linkers formed from Cu(I)-catalyzed cycloaddition reaction. Results: All synthesized compounds were investigated against Jurkat cells as acute T-cell leukemia and were potent apoptosis inducers at 50 nM. Conclusion: The effect of compound 2 in 0.05 μM on IMPDH degradation can be almost prevented by competition with bortezomib as the proteasome inhibitor at 0.1 and 0.5 μM.en
DOIhttps://doi.org/10.5812/ijpr-129251en
KeywordAnti-leukemiaen
KeywordInosine Monophosphate Dehydrogenaseen
KeywordMycophenolic Aciden
KeywordProteolysis-Targeting Chimerasen
KeywordTriazoleen
PublisherBrieflandsen
TitleSynthesis and Biological Evaluation of Novel Anti-leukemia Proteolysis-Targeting Chimeras in Degradating Inosine Monophosphate Dehydrogenaseen
TypeResearch Articleen

Files